Diagnostic

Tarsons Products is well positioned to gain from the surge in R&D investments in new molecules in the labware industry and demand for diagnostic services.

India now has most comprehensive TB test; can check sensitivity to 18 antibiotics

The test is the first of its kind to check for drug resistance to 18 antibiotics as well as detect co-infections, including non-tuberculous mycobacteria and mixed infections

This test package promises faster and better diagnosis of PCOS in women

Polycystic ovary syndrome is a common endocrine disorder predominantly affecting women of reproductive age. Clinical manifestations are diverse, including overproduction of some male hormones, lack of ovulation, infertility, hair loss and increased risk of metabolic diseases, besides psychosocial dysfunction

ICMR scientist develops world’s first rapid, cost-effective kits to diagnose haemophilia, von Willebrand disease

This simple strip-based test can be performed at a Primary Healthcare Centre. It holds the potential to change the diagnostic landscape of bleeding disorders like haemophilia and von Willebrand disease (vWD), not only in India but in several other developing countries, which either lack proper diagnostic facilities or where existing facilities are not up to acceptable standards

Jubilant Life soars over 12% ; mcap rises by Rs 1,225 cr

Shares of Jubilant Life Sciences today ended with over 12 percent gains, adding Rs 1,224.82 crore to its market valuation, after the company said its subsidiary has signed long-term contracts in the US for supply of some of its diagnostic and therapeutic products.

Jubilant Life signs deals for diagnostic product supply

Jubilant Life Sciences today said its subsidiary has signed long-term contracts in the US for supply of some of its diagnostic and therapeutic products.

Dr Lal PathLabs Q2 profit rises 8-fold, margin expands to 30.4%

Diagnostic chain Dr Lal PathLabs has reported more than 8-fold increase in consolidated profit at Rs 52.5 crore for July-September quarter compared with Rs 6.2 crore in same period last year. It was partly driven by low base in year-ago period. The company had reported one-time loss of Rs 16.6 crore in Q2FY16.

Can sustain margins at 40%; a regulator is welcome: Thyrocare

A regulatory body for labs could help the unorganised sector as well as help mitigate risks for companies, says A Velumani, Chairman, CEO & MD of the company.

To build brand visibility, expand network: Dr Lal Pathlabs

The company has a strong presence in the north and east but sees a huge potential and opportunities to grow in south and west too said Om Manchanda, CEO, Dr Lal PathLabs.

Fortis Healthcare Q2 profit at Rs 34 cr

The company had posted a net loss of Rs 58.12 crore for the corresponding period of the previous fiscal, Fortis Healthcare said.

Budget 2012: 'Diagnostics must continue under no service tax category'

What is Metropolis Healthcare expecting from the budget 2012 – 2013? Health Care

Fortis arm acquires Singapore's Radlink-Asia; shrs up

Hospital chain operator Fortis Healthcare's offshore subsidiary Fortis Healthcare Singapore Pte has acquired 85% stake in Radlink-Asia Pte, an outpatient diagnostic and molecular imaging chain in the south east Asian nation for USD 62.9 million.